Hunter Perkins Capital Management LLC Has $24.11 Million Position in Labcorp Holdings Inc. $LH

Hunter Perkins Capital Management LLC lowered its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,106 shares of the medical research company’s stock after selling 8,488 shares during the quarter. Labcorp makes up 5.6% of Hunter Perkins Capital Management LLC’s portfolio, making the stock its 2nd biggest holding. Hunter Perkins Capital Management LLC’s holdings in Labcorp were worth $24,111,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LH. Dakota Wealth Management boosted its stake in Labcorp by 98.6% in the 3rd quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company’s stock worth $2,958,000 after purchasing an additional 5,116 shares during the period. Independent Advisor Alliance raised its position in shares of Labcorp by 166.6% during the third quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company’s stock valued at $3,477,000 after buying an additional 7,568 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Labcorp by 12.0% in the third quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company’s stock worth $12,859,000 after buying an additional 4,800 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Labcorp by 224.1% in the second quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock worth $259,734,000 after buying an additional 684,153 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Labcorp by 3.1% during the second quarter. Franklin Resources Inc. now owns 34,331 shares of the medical research company’s stock worth $9,012,000 after acquiring an additional 1,043 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

LH has been the topic of a number of research reports. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. increased their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Robert W. Baird raised their price objective on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Piper Sandler lifted their target price on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.82.

Labcorp Trading Down 1.4%

LH stock opened at $264.52 on Friday. The firm has a fifty day moving average price of $274.20 and a 200 day moving average price of $269.17. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The firm has a market cap of $21.80 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.80 and a beta of 1.01. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42.

Labcorp (NYSE:LH) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. During the same quarter in the prior year, the firm earned $3.45 earnings per share. Labcorp’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Friday, February 27th. Labcorp’s dividend payout ratio is currently 27.53%.

Insider Buying and Selling at Labcorp

In related news, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares of the company’s stock, valued at approximately $8,619,935.17. This trade represents a 4.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of Labcorp stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the transaction, the chief executive officer owned 80,773 shares of the company’s stock, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 16,113 shares of company stock worth $4,547,450 in the last 90 days. 0.84% of the stock is currently owned by insiders.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.